SC
ARQT icon

Syon Capital’s Arcutis Biotherapeutics ARQT Stock Holding History

Syon Capital’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$266K Buy
10,126
+119
+1% +$2.77K 0.01% 840
2026
Q1 		$236K Hold
10,007
– – 0.01% 826
2025
Q4 		$291K Hold
10,007
– – 0.01% 753
2025
Q3 		$189K Sell
10,007
-123
-1% -$1.94K 0.01% 790
2025
Q2 		$142K Sell
10,130
-632
-6% -$8.86K 0.01% 715
2025
Q1 		$168K Sell
10,762
-2,810
-21% -$39.6K 0.01% 555
2024
Q4 		$189K Buy
+13,572
New +$149K 0.02% 525

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Syon Capital's ARQT Position: Q2 2026 in Review

Syon Capital increased its Arcutis Biotherapeutics (ARQT) stake by 1.2% in Q2 2026, buying an estimated $2.77K and bringing the position to 10,126 shares worth $266K. The position accounts for 0.01% of the portfolio, ranked #840.

Syon Capital first reported a position in ARQT in Q4 2024 and has held it in 7 quarters since. The position peaked at $291K in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Syon Capital held 10,126 shares of Arcutis Biotherapeutics worth $266K as of Q2 2026.
  • Syon Capital bought 119 Arcutis Biotherapeutics shares in Q2 2026, an estimated $2.77K.
  • Arcutis Biotherapeutics made up 0.01% of Syon Capital's portfolio in Q2 2026, its #840 holding.
  • Syon Capital first reported a position in Arcutis Biotherapeutics in Q4 2024 and has held it in 7 quarters since.
  • Syon Capital's Arcutis Biotherapeutics position peaked at $291K in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Syon Capital's 13F filing for Q2 2026, filed 14 Aug 2026.